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Rabies is a threat in all parts of the world where animal reservoirs persists, including Eastern Europe and the Middle East. Rabies
experts from seven Middle East and Eastern European countries (Croatia, Egypt, Georgia, Iran, Serbia, Turkey, and Ukraine) met
fortwodaysinIstanbul,Turkey(June8-9,2010),toexchangeinformationontheepidemiologicalsituationconcerninghumanand
animal rabies in their respective countries and to discuss strategies for rabies elimination and control. They decided to establish a
regional network, the Middle East andEastern Europe Rabies Expert Bureau (MEEREB), a regional network of experts, to increase
collaborationin rabies prevention and control at the local, regional, and global levels.
1.Introduction
Rabies is a major public health problem causing approxi-
mately 55,000 human deaths every year, mainly in Asia and
Africa [1]. It is also a threat in other parts of the world
where animal reservoirs persist, as is the case in Middle East
countries. Rabies continues to be a signiﬁcant but underesti-
mated public health concern in the region and the situation
in some countries has worsened, given the deteriorating
environment [2, 3]. While rabies rarely occurs in humans in
mostofEasternEurope,thankstopost-exposure prophylaxis
(PEP), it remains present in animal reservoirs, particularly
in countries situated at the crossroad of Asia, Africa, and
Western Europe [4, 5].
A group of experts in infectious diseases, rabies, and vac-
cinology from various institutions in seven Middle East and
Eastern European countries met for two days in Istanbul.
They were invited through the Ministries of Health/national
CDCs, or directly through personal contacts. The number of
participants/countries was voluntarilylimited as the sole aim
of this initial meeting was to evaluate the feasibility/interest
of establishing a regional network. During this meeting,2 Advances in Preventive Medicine
participants exchanged information on the epidemiological
situation of rabies in their respective countries and discussed
speciﬁc issues and strategies for rabies elimination and con-
trol in their region. They focused on human rabies, but the
animal rabies situation was also discussed, since prevention
of human rabies requires the control of rabies reservoirs in
animals.
Participants agreed to establish an informal regional net-
work—the Middle East and Eastern Europe Rabies Expert
Bureau(MEEREB)—tocomplementtheAsianRabiesExpert
Bureau (AREB), established in 2004 [6–8]a n dA f r o R E B ,a
network of experts from French-speaking Africa, established
in 2008 [9, 10].
2.TheRabiesSituation
The rabies situation presented during the meeting is sum-
marized in Table 1. All countries represented at MEEREB
reported animal rabies, and in some countries where canine
rabies is prevalent, the disease still occurs in humans. Cats
also play a role as a vector especially in Ukraine, where,
according to the data presented, 12 outof 29 (41.4%)human
rabies cases in the last 10 years were transmitted by cats, and
in Turkeywhere therecentreappearance of thedisease in this
species is a concern.
I nC r o a t i aa n dS e r b i a ,n oh uman rabies case has been
reported for over 30 years. The last case in Croatia was
reported in 1964, and the last case in Serbia was in 1980:
rabid dogs caused both. Since then, there have been two-
imported cases of human rabies in Croatia. The absence of
cases in Serbia and Croatia can be explained by the fact that
rabies is present in wildlife only, vaccination of pet dogs
is mandatory, and PEP of animal bite victims is accessible
free of charge. However, rabies is still enzootic in the red
fox in these two countries, and sporadic cases spill over to
other wild animal species and domestic animals. In each
country, >1,500 animal-bite victims receive post-exposure
prophylaxis (PEP) annually. Human rabies immunoglobu-
lins (HRIG) are locally produced by the Zagreb Institute of
Immunology and by the Belgrade Blood Transfusion Insti-
tute of Serbia.
The speciﬁc rabies situation in Turkey was described;
dog-mediated urban rabies predominates, with foci in the
Istanbul region. However, fox rabies has been increasing
since 1999, especially in the western Aegeanregion where the
numbers of rabid dogs and foxes are approximately equal,
a situation unique to Turkey. Occasional rabies cases are
observed in the jackal, particularly around Istanbul. These
data have also been published recently [11]. One to two hu-
man cases are reported annually.
In Iran, rabiesisthemost importantzoonoticdisease and
has spread across the country including the central desert
areas; the most aﬀected provinces are located in the north-
east, east, and south. The country is spending an increasing
portion of its health budget on procurement of cell culture
rabies vaccines and immunoglobulins to meet the increasing
demand for rabies PEP. The number of people receiving PEP
in the 300 bite management centres across the country has
more than doubled between 1997 and 2009, while the rabies
mortality rate has decreased from 0.9 per million people in
the1980s[12]to0.02-0.03permillion peopleinrecentyears.
In Egypt, animal rabies is present both in urban areas
and ruralsettlements.Straydogsare themaintransmitters to
other animals and humans. The situation has been stable for
the last 10 years with an annual number of 80 human rabies
cases. Among the countries reporting data at the meeting,
it had the second highest human rabies incidence, following
Georgia where the number of reported admissions for PEP
following exposure to potentially rabid animals has been
increasing steadily (from ∼10,000 in 2000 up to 28,055PEP
in 2008—with a peak of ∼48,000 in 2006).
Severalofthe countries represented receive support from
the European Union (EU) for oral vaccination of foxes
(Croatia, Serbia, and Turkey) and dogs (Turkey) [11]. West-
ern Europe eliminated animal rabies through compulsory
vaccination of dogs and oral vaccination of wildlife [13],
but the persistence of rabies in animals along borders is
a permanent threat. This is illustrated by the reemergence
in 2008 of animal rabies in Italy in an area bordering
Slovenia, and it spread through the north-western provinces
[14, 15].
3.RabiesProphylaxis
According to WHO, immediate post-exposure vaccination is
recommended for category II exposure (nibbling of uncov-
ered skin, minor scratches, or abrasions without bleeding;)
and immediate vaccination and administration of rabies
immunoglobulin are recommended for category III (single
or multiple transdermal bites or scratches, contamination of
mucous membrane with saliva from licks, licks on broken
skin, exposures to bats). For categories II and III, thorough
washing and ﬂushing (for 15-minutes, if possible) with soap
ordetergentandcopiousamountsofwaterofallbitewounds
and scratches should be done immediately, or as early as
possible following the bite [16]. Intramuscular vaccination
consists of either a 5-dose (1 dose on each of days 0, 3, 7,
14, and 28) or a 4-dose schedule (2 doses on day 0—1 in
each of the 2 deltoid or thigh sites—followed by 1 dose on
each of days 7 and 21). An intradermal regimen (injection of
0.1ml at 2 sites—deltoid and thigh—on days 0, 3, 7, and 28)
may be used for people with category II and III exposures in
countries where the intradermal route has been endorsed by
national health authorities [16].
PEP is free of charge for the patient in all countries par-
ticipating in MEEREB, except Egypt, where rabies immuno-
globulin (RIG) is rarely administered, even to patients with
category III exposure. In Georgia, PEP is free of charge for
children under 18 years of age and adults without social
coverage. Modern cell culture rabies vaccines are used intra-
muscularly (IM) for pre- and post-exposure prophylaxis.
Most countries use 5-dose IM regimen (at days 0, 3, 7, 14,
and 28). In three countries (Egypt, Georgia, and Ukraine), a
6-dose IM vaccination schedule (with an additional dose at
day 90) is applied in compliance with the labeling of some
regionally produced rabies vaccines.Advances in Preventive Medicine 3
Table 1: Rabies epidemiology and management in the 7 countries represented at MEEREB.
Croatia Egypt Georgia Iran Serbia Turkey Ukraine
Main reservoir(s) Fox Dog Dog, jackal,
wolf
Dog, wolf,
fox, jackal F o x D o g ,f o x ,j a c k a l D o g ,f o x
Main vector(s) Dog, cat Dog Dog, cat Dog Dog, cat Dog Cat, dog
Human population
(estimates)∗ ∼4,500,000 ∼80,500,000 ∼4,600,000 ∼76,900,000 ∼7,300,000 ∼77,800,000 ∼45,500,000
Number of human
rabies cases reported
between 2000–2009
[1999–2009 for Turkey]
0 880 90 62 0 21 29
Human rabies cases
reported in 2009∗∗ 0 8 0 620 2 6
Estimated human rabies
incidence per million
(2009)∗∗
— 0.99 1.30 0.02 — 0.025 0.13
Number of PEP (2009) 1,750 ∼200,000 28,055 130,531 1,609 178,250 21,000
PEP incidence per
million people (2009)∗∗ 388 ∼2,485 6,100 1,700 220 2,290 461
PEP vaccinationregimen
4d o s e sI M
(Zagreb
2-1-1)
Rarely: 5
doses IM
(Essen)
6d o s e sI Mat
days 0, 3, 7,
14, 28, 90
6d o s e sI Mat
days 0, 3, 7,
14, 28, 90
5d o s e sI Mat
days 0, 3, 7,
14, 28
5d o s e sI Mat
days 0, 3, 7,
14, 28
5d o s e sI Mat
days 0, 3, 7, 14,
and 21 or 28
6d o s e sI Mat days 0,
3, 7, 14, 28, 90
Type of rabies
Immunoglobulin used
HRIG
(locally
produced)
HRIG
(private
sector)
ERIG (public
sector)
HRIG
(private
sector)
HRIG (public
sector)
HRIG
(locally
produced)
ERIG (public
sector)
HRIG (private
sector)
ERIG (locally
produced)
Number of PrEP in 2009
200
(population
at risk)
N.a.∗∗∗
Vets (on a
voluntary
basis)
N.a.
(population
at risk)
51
(population
at risk)
991 (population
at risk)
N.a. (population at
risk)
Figures reported by MEEREB participants.
∗July 2010 estimates—The World Fact Book—https://www.cia.gov/library/publications/the-world-factbook/.
∗∗Calculated from data reported by participants for the population mentioned.
∗∗∗N.a.: data not available.
Human rabies immunoglobulin (HRIG) is used in the
public sector in Serbia, Croatia, and Iran. In the other coun-
tries, it is available in the private sector only, while equine
rabies immunoglobulin (ERIG) is used in the public sector
and produced in Ukraine for local use.
Pre-exposure prophylaxis (PrEP) is administered free of
charge to people at high risk of exposure in most MEEREB
countries, as recommended by WHO [16]. The exceptions
are Georgia and Egypt, where it is provided on a voluntary
basis. Those vaccinated pay for the treatment.
4.Discussion
This meeting was a ﬁrst step in establishing a rabies network
in the Middle East and Eastern Europe. During this initial
meeting, participants noted the common issues and diﬀer-
ences in their respective rabies situation and discussed how
they couldbeneﬁt from sharing their experiences to establish
a regular, supranational collaboration to ﬁght rabies.
Itwas notedthatdataonhuman rabies casesare available
at the national level, but that they need to be consolidated
and made available at the international level. For instance, 2
and 6 humancaseswere reported tohave occurredin2009in
Turkey and Ukraine, respectively (Table 1) ,w h i l en o n ew a s
reported to the Rabies Bulletin Europe [17].
Human cases still occur in countries where rabies is pre-
sent in dogs, in spite of vaccine and RIG availability.
Strengthening dog vaccination and dog population control
is key to rabies control. It was reported at the meeting that
among the 1-1.2 million privately-owned dogs in Iran,
approximately 400,000 are vaccinated, while there is no
vaccination programme for unowned and stray dogs, the
estimated number of which is about 1 million [12]. This
results in an estimated 15–20% vaccination coverage for the
dog population, which is insuﬃcient, since vaccinating at
least 70% of the whole dog population is necessary for dog
rabies control [18]. The situation is even less clear for cats.
Therefore, the Blueprint for Rabies Prevention and Con-
trol that was previewed during the MEEREB workshop was4 Advances in Preventive Medicine
enthusiastically welcomed by the participants as it helps and
guides those implementing rabies control programmes for
dog-rabies elimination with a detailed step-by-step action
plan. This paper has been prepared by a global group of
rabies experts (Partners for Rabies Prevention) under the
leadership of the Global Alliance for Rabies Control (GARC)
and is available online and can be downloaded free of charge
[19].
Furthermore, MEEREB participants noted the need to
increase rabies awareness in their region, and agreed to par-
ticipateintheWorldRabiesDay.Theyalsonotedtheneedfor
timely information for people travelling to rabies enzootic
areas (i.e.,travellersto theirregionsand/orpeople fromtheir
regions to other enzootic parts of the world). Recent studies
showed that most animal-associated injuries requiring PEP
in French travellers occur during visits to Thailand and
Turkey—countries for which travellers do not usually seek
advice since they are not associated with more conventional
travel-associated diseases like malaria or yellow fever [20].
The majority of travellers bitten by animals do not receive
adequate PEP, or else they experience a substantial delay
before receiving it [20–23].
The participants agreed to meet regularly and to invite
experts from other countries of the region to join the
MEEREB network, and participate in the next MEEREB
workshop.
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